ADCO-IBUPROFEN 400 mg

Country: South Africa

Language: English

Source: South African Health Products Regulatory Authority (SAHPRA)

Available from:

Adcock

Patient Information leaflet

INDICATIONS [/za_107.html#1]
  [/za_107.html#1]     [/za_107.html#1]
CONTRA-INDICATIONS [/za_107.html#1]
      [/za_107.html#1]
DOSAGE [/za_107.html#1]
      [/za_107.html#1]
SIDE-EFFECTS [/za_107.html#1]
  [/za_107.html#1]     [/za_107.html#1]
PREGNANCY [/za_107.html#1]
      [/za_107.html#1]
OVERDOSE [/za_107.html#1]

IDENTIFICATION [/za_107.html#1]
  [/za_107.html#1]    PATIENT INFORMATION
ADCO-IBUPROFEN 400 MG
SCHEDULING STATUS:
S3
PROPRIETARY NAME
(and dosage form):
ADCO-IBUPROFEN 400 MG
TABLETS
COMPOSITION:
Each sugar-coated tablet contains 400 mg 
IBUPROFEN
.
Contains TARTRAZINE.
Contains Sugar.
PHARMACOLOGICAL CLASSIFICATION:
A. 3.1 Anti-rheumatics (Anti-inflammatory Agents)
PHARMACOLOGICAL ACTION: 
ADCO-IBUPROFEN contains ibuprofen, which is a non-steroidal, anti-inflammatory, antipyretic and analgesic agent. It
inhibits the synthesis of prostaglandins. Ibuprofen is absorbed from the gastro-intestinal tract producing peak plasma
concentrations after one to two hours. 
INDICATIONS: 
ADCO-IBUPROFEN is indicated in the treatment of rheumatoid arthritis, osteo-arthritis and ankylosing spondylitis,
Still's disease (juvenile rheumatoid arthritis), fibrositis, musculoskeletal pain, swelling and inflammation due to trauma. 
CONTRA-INDICATIONS: 
It should be given with care to patients with peptic ulceration or a history of such ulceration, bleeding disorders,
cardiovascular disease and those on oral anticoagulants. It should not be given to patients who are sensitive to aspirin.
ADCO-IBUPROFEN should be administered with care in patients with asthma, especially those who have developed
bronchospasm with other non-steroidal agents. 
WARNINGS:
Contains tartrazine, which may cause allergic type reactions (including bronchial asthma) in certain individuals. The
overall incidence of tartrazine sensitivity is low; it is h